{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:46:22Z","timestamp":1747183582663,"version":"3.40.5"},"reference-count":14,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T00:00:00Z","timestamp":1658880000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Outcomes remain poor for patients with relapsed\/refractory B\u2010cell non\u2010Hodgkin lymphoma (R\/R B\u2010NHL). While chimeric antigen receptor (CAR) T\u2010cell therapy has revolutionised treatment, a significant proportion of patients relapse or fail to respond. Odronextamab is a CD20\u2009\u00d7\u2009CD3 bispecific antibody that has demonstrated durable responses and a manageable safety profile in patients with R\/R B\u2010NHL in a first\u2010in\u2010human trial (NCT02290951). Here, we document two patients with diffuse large B\u2010cell lymphoma refractory to CART\u2010cell therapy. Both achieved complete responses that remain ongoing for \u22652\u2009years following odronextamab. Neither patient experienced Grade \u22653 cytokine release syndrome or Grade \u22653 neurological adverse events during treatment.<\/jats:p>","DOI":"10.1111\/bjh.18383","type":"journal-article","created":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T08:14:30Z","timestamp":1658909670000},"page":"366-370","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Complete responses to odronextamab in two patients with diffuse large B\u2010cell lymphoma refractory to chimeric antigen receptor T\u2010cell therapy"],"prefix":"10.1111","volume":"199","author":[{"given":"Matt","family":"Weinstock","sequence":"first","affiliation":[{"name":"Hematology\/Oncology Beth Israel Deaconess Medical Center  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavania","family":"Elavalakanar","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology Beth Israel Deaconess Medical Center  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Bright","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology Beth Israel Deaconess Medical Center  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srikanth R.","family":"Ambati","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc.  Tarrytown New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jurriaan","family":"Brouwer\u2010Visser","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc.  Tarrytown New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephane","family":"Pourpe","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc.  Tarrytown New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Fiaschi","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc.  Tarrytown New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Jankovic","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc.  Tarrytown New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gavin","family":"Thurston","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc.  Tarrytown New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel P.","family":"Deering","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc.  Tarrytown New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aafia","family":"Chaudhry","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc.  Tarrytown New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Joyce","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology Beth Israel Deaconess Medical Center  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9038-7277","authenticated-orcid":false,"given":"Jon","family":"Arnason","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology Beth Israel Deaconess Medical Center  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,7,27]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1706169"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25505"},{"issue":"1","key":"e_1_2_5_8_1","first-page":"595","article-title":"Real\u2010world treatment patterns among patients with diffuse large B\u2010cell lymphoma (DLBCL) treated with CD19\u2010directed chimeric antigen receptor T\u2010cell therapy (CART)","volume":"4","author":"Jalbert JJ","year":"2020","journal-title":"HemaSphere"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00072-2"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.5714"},{"issue":"1","key":"e_1_2_5_12_1","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1182\/blood-2019-127683","article-title":"Multiplexed immunofluorescence (IF) analysis and gene expression profiling of biopsies from patients with relapsed\/refractory (R\/R) diffuse large B cell lymphoma (DLBCL) treated with lisocabtagene maraleucel (liso\u2010cel) in TRANSCEND NHL 001 reveal patterns of immune infiltration associated with durable response","volume":"134","author":"Reiss DJ","year":"2019","journal-title":"Blood"},{"issue":"1","key":"e_1_2_5_13_1","first-page":"194","article-title":"Predicting clinical response and safety of JCAR017 in B\u2010NHL patients: potential importance of tumor microenvironment biomarkers and CART\u2010cell tumor infiltration","volume":"130","author":"Swanson C","year":"2017","journal-title":"Blood"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0184-6"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.25606"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.18383","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.18383","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.18383","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T13:15:13Z","timestamp":1692623713000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.18383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,27]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1111\/bjh.18383"],"URL":"https:\/\/doi.org\/10.1111\/bjh.18383","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"type":"print","value":"0007-1048"},{"type":"electronic","value":"1365-2141"}],"subject":[],"published":{"date-parts":[[2022,7,27]]},"assertion":[{"value":"2022-05-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}